DK9290D0 - Praeparat, isaer til forhindring af infektioner hos dyr - Google Patents

Praeparat, isaer til forhindring af infektioner hos dyr

Info

Publication number
DK9290D0
DK9290D0 DK009290A DK9290A DK9290D0 DK 9290 D0 DK9290 D0 DK 9290D0 DK 009290 A DK009290 A DK 009290A DK 9290 A DK9290 A DK 9290A DK 9290 D0 DK9290 D0 DK 9290D0
Authority
DK
Denmark
Prior art keywords
csf
isaar
prevention
preparation
genetically engineered
Prior art date
Application number
DK009290A
Other languages
English (en)
Other versions
DK175245B1 (da
DK9290A (da
Inventor
Thomas C Boone
Allan L Miller
Jeffrey W Andresen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DK9290D0 publication Critical patent/DK9290D0/da
Publication of DK9290A publication Critical patent/DK9290A/da
Application granted granted Critical
Publication of DK175245B1 publication Critical patent/DK175245B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Filling Or Discharging Of Gas Storage Vessels (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
DK199000092A 1988-05-13 1990-01-12 Fremgangsmåde til isolering og rensning af granulocyt kolonistimulerende faktor (G-CSF) fra en mikroorganisme, der producerer rekombinant G-CSF DK175245B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US19385788A 1988-05-13 1988-05-13
US19385788 1988-05-13
US34801189A 1989-05-09 1989-05-09
US34801189 1989-05-09
US8902057 1989-05-12
PCT/US1989/002057 WO1989010932A1 (en) 1988-05-13 1989-05-12 Compositions and method for treating or preventing infections in animals

Publications (3)

Publication Number Publication Date
DK9290D0 true DK9290D0 (da) 1990-01-12
DK9290A DK9290A (da) 1990-03-09
DK175245B1 DK175245B1 (da) 2004-07-19

Family

ID=26889429

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199000092A DK175245B1 (da) 1988-05-13 1990-01-12 Fremgangsmåde til isolering og rensning af granulocyt kolonistimulerende faktor (G-CSF) fra en mikroorganisme, der producerer rekombinant G-CSF

Country Status (12)

Country Link
US (1) US5849883A (da)
EP (2) EP0719860B1 (da)
JP (1) JP2796388B2 (da)
KR (1) KR0133561B1 (da)
AT (1) ATE452190T1 (da)
AU (3) AU636127B2 (da)
DE (1) DE68929566D1 (da)
DK (1) DK175245B1 (da)
FI (1) FI900178A0 (da)
NO (1) NO300217B1 (da)
NZ (1) NZ229098A (da)
WO (1) WO1989010932A1 (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
EP0719860B1 (en) 1988-05-13 2009-12-16 Amgen Inc. Process for isolating and purifying G-CSF
JPH04502164A (ja) * 1989-10-10 1992-04-16 アムジエン・インコーポレーテツド 犬科・猫科動物における感染の治療または予防のための化学組成物及び方法
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
EP0777733A1 (en) * 1994-08-19 1997-06-11 Embrex, Inc. Method of treating birds with avian myelomonocytic growth factor
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
DK0988861T3 (da) * 1998-08-17 2004-04-19 Pfizer Prod Inc Stabiliserede proteinpræparater
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
ATE269716T1 (de) 2000-02-29 2004-07-15 Pfizer Prod Inc Stabilisierter granulozyten-kolonie- stimulierender faktor
AU9084601A (en) 2000-09-08 2002-03-22 Massachusetts Inst Technology G-csf analog compositions and methods
KR100961859B1 (ko) 2001-07-11 2010-06-09 맥시겐 홀딩스 엘티디 지-씨에스에프 접합체
SI21102A (sl) * 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
EP1490402A4 (en) 2002-03-20 2007-05-02 Biopolymed Inc PREPARATION OF CYSTEINREST STOCHIOMETRIC WITH BIOKOMPATIBLE POLYMER CONJUGATED G-CSF
AU2002345829A1 (en) * 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
WO2005025593A2 (en) * 2003-05-09 2005-03-24 Schering Aktiengesellschaft Treatment of inflammatory respiratory diseases
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
RU2385878C2 (ru) 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
KR20140011431A (ko) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
CA2580991A1 (en) * 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
EP2360180A3 (en) 2004-12-13 2012-02-08 Amylin Pharmaceuticals Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US9176145B2 (en) 2006-07-21 2015-11-03 Femalon S.P.R.L. Kit for predicting implantation success in assisted fertilization
WO2008116470A1 (en) * 2007-03-26 2008-10-02 Drugrecure Aps Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor
US8546328B2 (en) 2007-08-27 2013-10-01 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN102089319B (zh) 2008-05-08 2013-11-13 味之素株式会社 蛋白质的重折叠方法
EP2318029B1 (en) * 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
SG176963A1 (en) 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
LT3660032T (lt) 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
CN102573888A (zh) 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
BR112012022518A2 (pt) 2010-03-17 2020-10-13 Biogenerix Gmbh método para obtenção de g- csf recombinante humano biologicamente ativo
RU2487885C2 (ru) * 2010-07-20 2013-07-20 Зао "Биокад" Способ крупномасштабного получения, выделения и очистки рекомбинантного гранулоцитарного колониестимулирующего фактора человека
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
HUP1200172A2 (en) * 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
EP2855517A1 (en) 2012-05-29 2015-04-08 Novo Nordisk A/S Pancreatic polypeptide compounds and use
US9982012B2 (en) 2013-03-29 2018-05-29 Dr. Reddy's Laboratories Limited Refolding of granulocyte colony stimulating factor
WO2019075053A1 (en) * 2017-10-11 2019-04-18 Elanco Us Inc. PORCINE G-CSF VARIANTS AND USES THEREOF
WO2020234742A1 (en) * 2019-05-20 2020-11-26 Lupin Limited Granulocyte colony stimulating factor purification
EP3996828A4 (en) * 2019-07-09 2023-09-06 Tanvex Biopharma Usa, Inc. TEMPERATURE-CONTROLLED PURIFICATION OF GRANULOCYTE COLONY STIMULATING FACTOR

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2438821A1 (fr) * 1978-10-13 1980-05-09 France Etat Dispositif d'allumage a fil chaud de securite
US4618600A (en) * 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
JPS6145010A (ja) * 1984-08-08 1986-03-04 Setsuji Umezaki 埋立地の造成方法
JPH0615477B2 (ja) * 1985-02-08 1994-03-02 中外製薬株式会社 感染防禦剤
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4721420A (en) * 1985-09-03 1988-01-26 Arthur D. Little, Inc. Pipeline transportation of coarse coal-liquid carbon dioxide slurry
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
AU621051B2 (en) * 1987-04-28 1992-03-05 Amgen, Inc. Method for purifying granulocyte-macrophage colony stimulating factor
ATE121418T1 (de) * 1987-10-23 1995-05-15 Schering Corp Verfahren zur proteinreinigung.
EP0719860B1 (en) 1988-05-13 2009-12-16 Amgen Inc. Process for isolating and purifying G-CSF

Also Published As

Publication number Publication date
KR0133561B1 (ko) 1998-04-21
AU4197393A (en) 1993-10-28
NZ229098A (en) 1992-10-28
DE68929566D1 (de) 2010-01-28
ATE452190T1 (de) 2010-01-15
NO900185L (no) 1990-03-12
US5849883A (en) 1998-12-15
JPH02504521A (ja) 1990-12-20
EP0347041A2 (en) 1989-12-20
AU636127B2 (en) 1993-04-22
DK175245B1 (da) 2004-07-19
AU4197293A (en) 1993-10-28
KR900701824A (ko) 1990-12-04
WO1989010932A1 (en) 1989-11-16
FI900178A7 (fi) 1990-01-12
NO900185D0 (no) 1990-01-12
AU4781290A (en) 1990-11-15
AU661172B2 (en) 1995-07-13
JP2796388B2 (ja) 1998-09-10
DK9290A (da) 1990-03-09
FI900178A0 (fi) 1990-01-12
EP0719860A1 (en) 1996-07-03
NO300217B1 (no) 1997-04-28
EP0719860B1 (en) 2009-12-16
EP0347041A3 (en) 1990-11-22

Similar Documents

Publication Publication Date Title
DK9290A (da) Praeparat, isaer til forhindring af infektioner hos dyr
AU633714B2 (en) New uses of l-deprenyl and compositions for same
DK47189A (da) Bredspektret konserveringsmiddel med synergistisk biocidvirkning
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
DK0608912T3 (da) Synergistiske mikrobicide sammensætninger
LV10203A (lv) Panemiens inficesanas ar AIDS noteiksanai olbaltumvielu kompozicija test-komplekts
DK16890D0 (da) Antiviral eller antibakteriel forbindelse og frem gangsmaade til anvendelse heraf
DE69532921D1 (de) Angesäuertes nitrit zur verwendung als antimikrobielles mittel
FR2751879B1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU2861389A (en) Disubstituted pyridines
DE3685484D1 (da)
DK536284A (da) Antipancreasinflammationspraeparater
AU2085392A (en) Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
DK1043028T3 (da) Phytase til forebyggelse eller behandling af mastitis
EP0706786A3 (de) Verwendung von Chlorogensäure als Antioxidans in kosmetischen, insbesondere haarkosmetischen Zubereitungen, sowie Zubereitungen, Chlorogensaüre enthaltend
IT9048066A0 (it) 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono.
TW368393B (en) Poison bait for controlling noxious insects
DE69215203D1 (de) Verwendung von Dioldiestern in Hunde- und Katzenfutter
WO2002074922A3 (en) Compositions and methods for modulating an immune response
WO1992018090A3 (en) Antimicrobial oral compositions
DE69003216D1 (de) Verwendung von somatostatin.

Legal Events

Date Code Title Description
PUP Patent expired